Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Gross Margin (2016 - 2025)

Lineage Cell Therapeutics' Gross Margin history spans 15 years, with the latest figure at 99.0% for Q4 2025.

  • For Q4 2025, Gross Margin rose 437.0% year-over-year to 99.0%; the TTM value through Dec 2025 reached 99.0%, up 251.0%, while the annual FY2025 figure was 99.0%, 251.0% up from the prior year.
  • Gross Margin reached 99.0% in Q4 2025 per LCTX's latest filing, down from 99.86% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.86% in Q3 2025 to a low of 1.93% in Q4 2021.
  • Average Gross Margin over 5 years is 86.41%, with a median of 94.84% recorded in 2023.
  • Peak YoY movement for Gross Margin: plummeted -6596bps in 2021, then skyrocketed 9275bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 1.93% in 2021, then surged by 4810bps to 94.67% in 2022, then dropped by -7bps to 87.74% in 2023, then increased by 8bps to 94.63% in 2024, then rose by 5bps to 99.0% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Gross Margin are 99.0% (Q4 2025), 99.86% (Q3 2025), and 98.59% (Q2 2025).